Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in adolescent schizophrenia
NCT01911429Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma America. Started Aug 2013; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01911429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01911429.